Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.61 |
| ▸ | HTR1A | P08908 | 8/20 | 0.61 |
| ▸ | DRD3 | P35462 | 8/20 | 0.61 |
| ▸ | HTR2A | P28223 | 7/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.61 |
| ▸ | DRD1 | P21728 | 3/20 | 0.61 |
| ▸ | DRD5 | P21918 | 3/20 | 0.61 |
| ▸ | HRH1 | P35367 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090615 | 0.98 | DRD2 (0.59) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL2095204 | 0.95 | DRD2 (0.58) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL8011318 | 0.91 | DRD2 (0.69) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL2091554 | 0.88 | HTR1A (0.56) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL3197906 | 0.83 | CYP2D6 (0.63) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL9757322 | 0.83 | HTR1A (0.61) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL9757260 | 0.83 | DRD2 (0.61) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL13875126 | 0.83 | KDM4E (0.69) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL2094432 | 0.83 | KDM4E (0.69) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL2091821 | 0.83 | KCNH2 (0.79) | DRD2HTR1ADRD3HTR2ATMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | DRD2 409/4885HTR1A 3561/4885DRD3 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.